AstraZeneca pipeline at a glance (March 2026)
About the AstraZeneca clinical program
AstraZeneca operates one of the broadest oncology pipelines in the industry, with particular depth in lung cancer (Tagrisso/osimertinib and successors), ovarian and breast cancer (Lynparza/olaparib), and immuno-oncology (Imfinzi/durvalumab). The AstraZeneca/Daiichi-Sankyo collaboration on antibody-drug conjugates — including Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan — has reshaped the ADC landscape across HER2-expressing tumors. Outside oncology, AstraZeneca's CVRM franchise (Farxiga/dapagliflozin, Brilinta/ticagrelor) continues expanding indications into heart failure and chronic kidney disease.
Key therapeutic areas
- Oncology
- Lung cancer (EGFR/ALK/HER2)
- Ovarian cancer
- Breast cancer ADCs
- Cardiovascular / Metabolic
- Rare disease
Key pipeline programs
- Tagrisso (osimertinib) — EGFR-mutant NSCLC
- Lynparza (olaparib) — BRCA-mutated cancers
- Imfinzi (durvalumab) — PD-L1 checkpoint
- Enhertu (trastuzumab deruxtecan) — HER2 ADC
- Dato-DXd (datopotamab deruxtecan) — TROP2 ADC
- Calquence (acalabrutinib) — B-cell malignancies
Monitor the AstraZeneca pipeline daily
Get alerts when AstraZeneca registers new trials or updates existing protocols. Free 14-day trial — no credit card required.
Start Monitoring FreeTop AstraZeneca trial indications
| Condition / Indication | Trials |
|---|---|
| ["Asthma"] | 22 |
| ["Breast Cancer"] | 13 |
| ["Healthy Participants"] | 13 |
| ["Non-small Cell Lung Cancer"] | 11 |
| ["Chronic Obstructive Pulmonary Disease (COPD)"] | 10 |
| ["Systemic Lupus Erythematosus"] | 9 |
| ["Non-Small Cell Lung Cancer"] | 9 |
| ["Severe Asthma"] | 7 |
Why monitor AstraZeneca's clinical trial activity
AstraZeneca registers new combination trials for its ADC portfolio monthly. Monitoring their pipeline helps identify new competitive entries into HER2, TROP2, and EGFR-targeted spaces before they appear in analyst reports.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to AstraZeneca's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks AstraZeneca trials
- Sponsor normalization: AstraZeneca may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your AstraZeneca pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Start Free TrialFrequently asked questions
What therapeutic areas does AstraZeneca focus on in clinical trials?
AstraZeneca's active pipeline is heaviest in oncology (lung, ovarian, breast, blood cancers) followed by cardiovascular/metabolic disease and respiratory conditions. Their oncology-IO collaboration with Daiichi Sankyo means ADC programs are a growing share of new registrations.
How many AstraZeneca trials are currently recruiting?
Based on current ClinicalTrials.gov data indexed by DataLookout, 211 AstraZeneca-sponsored trials are actively recruiting. This includes industry-sponsored studies where AstraZeneca or its collaboration partners are the lead sponsor.
Can I track AstraZeneca trial updates — not just new registrations?
Yes. DataLookout monitors field-level changes to existing trial records: status transitions (e.g., active-not-recruiting → recruiting), site additions, enrollment count updates, and protocol amendments. Set a watchlist for AstraZeneca to receive these updates daily.